{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:25:46Z","timestamp":1793273146499,"version":"4.5.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Clinical Research Fund"},{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biora Therapeutics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Inflammatory bowel disease management has advanced with therapies like Janus kinase inhibitors (JAKi). Despite their promise, JAKi pharmacokinetic-pharmacodynamic (PK-PD) profiles and tissue-level effects remain underexplored. This study investigates tissue and serum tofacitinib levels, their correlation with therapeutic efficacy, and molecular mechanisms underlying treatment response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Thirty refractory ulcerative colitis (UC) patients receiving tofacitinib were prospectively studied. Tissue biopsies and serum samples were collected pre- and post-induction for PK analysis using liquid chromatography mass spectrometry. RNA sequencing and cytokine profiling were performed on tissue samples to explore molecular responses. Endoscopic improvement was defined as a Mayo endoscopic subscore of 0-1 by week 16.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Tofacitinib tissue concentrations were 25-fold higher than serum levels and significantly correlated (\u03c1=0.92, P\u2005&amp;lt;\u2005.001). Responders showed significantly higher tissue drug exposure (1047.5\u00a0ng\/g vs 467.1\u00a0ng\/g, P\u2005=\u2005.02) at the time of endoscopic assessment. Tofacitinib treatment reduced phosphorylated STAT3 (pSTAT3) levels, particularly in responders (P\u2005=\u2005.02). RNA sequencing revealed gene modules linked to tissue drug and pSTAT3 concentrations. Gene set enrichment analysis showed that these were more frequent in non-responders and associated with JAK-STAT pathways.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study underscores the importance of tissue tofacitinib levels in UC treatment efficacy, with pSTAT3 reduction serving as a potential marker of drug efficacy. RNA sequencing identified molecular pathways for potential biomarkers and novel therapeutic targets in tofacitinib non-responders.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf063","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T12:22:17Z","timestamp":1744892537000},"source":"Crossref","is-referenced-by-count":8,"title":["Drug tissue concentration and STAT3 modulation as determinants of tofacitinib response in ulcerative colitis"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3898-7093","authenticated-orcid":false,"given":"Bram","family":"Verstockt","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven , KU Leuven, Leuven ,","place":["Belgium"]},{"name":"Translational Research in Gastrointestinal Disorders, Department of Chronic Disease and Metabolism , KU Leuven, Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6795-6328","authenticated-orcid":false,"given":"Dahham","family":"Alsoud","sequence":"additional","affiliation":[{"name":"Translational Research in Gastrointestinal Disorders, Department of Chronic Disease and Metabolism , KU Leuven, Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"van Oostrom","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology , Amsterdam UMC, Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6222-8527","authenticated-orcid":false,"given":"Sare","family":"Verstockt","sequence":"additional","affiliation":[{"name":"Translational Research in Gastrointestinal Disorders, Department of Chronic Disease and Metabolism , KU Leuven, Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Smith","sequence":"additional","affiliation":[{"name":"Biora Therapeutics , San Diego California, San Diego, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Stylli","sequence":"additional","affiliation":[{"name":"Biora Therapeutics , San Diego California, San Diego, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujay","family":"Singh","sequence":"additional","affiliation":[{"name":"Biora Therapeutics , San Diego California, San Diego, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"van Gennep","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology , Amsterdam UMC, Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pejman","family":"Rahimian","sequence":"additional","affiliation":[{"name":"Biora Therapeutics , San Diego California, San Diego, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Sabino","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven , KU Leuven, Leuven ,","place":["Belgium"]},{"name":"Translational Research in Gastrointestinal Disorders, Department of Chronic Disease and Metabolism , KU Leuven, Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-0716","authenticated-orcid":false,"given":"Marc","family":"Ferrante","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven , KU Leuven, Leuven ,","place":["Belgium"]},{"name":"Translational Research in Gastrointestinal Disorders, Department of Chronic Disease and Metabolism , KU Leuven, Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariella","family":"Kelman","sequence":"additional","affiliation":[{"name":"Biora Therapeutics , San Diego California, San Diego, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharat","family":"Singh","sequence":"additional","affiliation":[{"name":"Biora Therapeutics , San Diego California, San Diego, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"D\u2019Haens","sequence":"additional","affiliation":[{"name":"Translational Research in Gastrointestinal Disorders, Department of Chronic Disease and Metabolism , KU Leuven, Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9942-3019","authenticated-orcid":false,"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven , KU Leuven, Leuven ,","place":["Belgium"]},{"name":"Translational Research in Gastrointestinal Disorders, Department of Chronic Disease and Metabolism , KU Leuven, Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"2025060311001696800_CIT0001","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis."},{"key":"2025060311001696800_CIT0002","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis."},{"key":"2025060311001696800_CIT0003","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/17512433.2021.2028619","article-title":"Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases","volume":"14","author":"Kantasiripitak","year":"2021","journal-title":"Expert Rev Clin Pharmacol."},{"key":"2025060311001696800_CIT0004","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"2025060311001696800_CIT0005","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41575-021-00574-7","article-title":"Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease","volume":"19","author":"Verstockt","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"2025060311001696800_CIT0006","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med."},{"key":"2025060311001696800_CIT0007","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/gutjnl-2014-308099","article-title":"The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the atlas study","volume":"65","author":"Yarur","year":"2016","journal-title":"Gut."},{"key":"2025060311001696800_CIT0008","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/ecco-jcc\/jjaa239","article-title":"Tissue exposure does not explain non-response in ulcerative colitis patients with adequate serum vedolizumab concentrations","volume":"15","author":"Van den Berghe","year":"2021","journal-title":"J Crohns Colitis."},{"key":"2025060311001696800_CIT0009","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/ecco-jcc\/jjac067","article-title":"Real-world endoscopic and histological outcomes are correlated with ustekinumab exposure in patients with ulcerative colitis","volume":"16","author":"Alsoud","year":"2022","journal-title":"J Crohns Colitis."},{"key":"2025060311001696800_CIT0010","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/apt.16955","article-title":"Longitudinal monitoring of stat3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis","volume":"56","author":"Verstockt","year":"2022","journal-title":"Aliment Pharmacol Ther."},{"key":"2025060311001696800_CIT0011","doi-asserted-by":"crossref","first-page":"jjae200","DOI":"10.1093\/ecco-jcc\/jjae200","article-title":"Anti-TNF nonresponse in ulcerative colitis: correcting for mucosal drug exposure reveals distinct cytokine profiles","volume":"19","author":"van Oostrom","year":"2025","journal-title":"J Crohns Colitis."},{"key":"2025060311001696800_CIT0012","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.cgh.2019.08.030","article-title":"Expression levels of 4 genes in colon tissue might be used to predict which patients will enter endoscopic remission after vedolizumab therapy for inflammatory bowel diseases","volume":"18","author":"Verstockt","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025060311001696800_CIT0013","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/apt.15126","article-title":"Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn\u2019s disease","volume":"49","author":"Verstockt","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"2025060311001696800_CIT0014","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.3317","article-title":"HISAT: a fast spliced aligner with low memory requirements","volume":"12","author":"Kim","year":"2015","journal-title":"Nat Methods."},{"key":"2025060311001696800_CIT0015","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq--a python framework to work with high-throughput sequencing data","volume":"31","author":"Anders","year":"2015","journal-title":"Bioinformatics."},{"key":"2025060311001696800_CIT0016","doi-asserted-by":"crossref","first-page":"D710","DOI":"10.1093\/nar\/gkv1157","article-title":"Ensembl 2016","volume":"44","author":"Yates","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"2025060311001696800_CIT0017","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/ecco-jcc\/jjaa049","article-title":"Development of gut-selective pan-janus kinase inhibitor td-1473 for ulcerative colitis: a translational medicine programme","volume":"14","author":"Sandborn","year":"2020","journal-title":"J Crohns Colitis."},{"key":"2025060311001696800_CIT0018","doi-asserted-by":"crossref","first-page":"S978","DOI":"10.14309\/01.ajg.0001034848.57615.ac","article-title":"S1370 single ascending dose results from a phase 1 clinical trial of bt-600, a combination product of the NaviCap targeted oral delivery platform and tofacitinib","volume":"119","author":"Feagan","year":"2024","journal-title":"Am J Gastroenterol."},{"key":"2025060311001696800_CIT0019","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41392-020-00384-4","article-title":"The bet family in immunity and disease","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct Target Ther."},{"key":"2025060311001696800_CIT0020","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/eji.201444862","article-title":"BET bromodomain inhibition suppresses transcriptional responses to cytokine-JAK-STAT signaling in a gene-specific manner in human monocytes","volume":"45","author":"Chan","year":"2015","journal-title":"Eur J Immunol."},{"key":"2025060311001696800_CIT0021","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ccell.2017.12.007","article-title":"Bet\u2019ing on dual JAK\/BET inhibition as a therapeutic strategy for myeloproliferative neoplasms","volume":"33","author":"Jiang","year":"2018","journal-title":"Cancer Cell."},{"key":"2025060311001696800_CIT0022","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/apt.17753","article-title":"The assessment of segmental healing by the modified mayo endoscopic score (MMES) complements the prediction of long-term clinical outcomes in patients with ulcerative colitis","volume":"59","author":"Lenfant","year":"2024","journal-title":"Aliment Pharmacol Ther."}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf063\/62945975\/jjaf063.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/5\/jjaf063\/62945975\/jjaf063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/5\/jjaf063\/62945975\/jjaf063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T15:01:35Z","timestamp":1748962895000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf063\/8115425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf063","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,4,17]]},"article-number":"jjaf063"}}